Ranbaxy Laboratories Ltd (RANB.BO)
|Market Cap (Mil.):||Rs149,270.00|
|Shares Outstanding (Mil.):||423.10|
BRUSSELS - European antitrust regulators fined nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, a total of 146 million euros for blocking the supply of a cheaper anti-depressant to the market, the first EU sanction against such deals.
MUMBAI, June 13 - Ranbaxy Laboratories, India's No.1 drugmaker by sales, plans to file three to four generic drug applications every year that can earn it a six-month marketing exclusivity in the United States, the company's chief executive said on Thursday.
Reuters Market Eye - Shares in pharmaceutical companies are leading the gains on Tuesday due to factors such as value-buying and expectations that promoters may increase stake in some companies, dealers say.
BRUSSELS - A European regulator will fine Denmark's Lundbeck , India's Ranbaxy and seven other makers of generic drugs for limiting the supply of cheaper medicines, two people with knowledge of the matter said, its first sanction against "pay-for-delay" deals.
MUMBAI - Shares in Ranbaxy Laboratories Ltd fell as much as 10.7 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believed former shareholders of the Indian company hid information regarding U.S. regulatory probes.
(Adds response from Singh family, details; updates share price)
MUMBAI - Ranbaxy Laboratories Ltd slumped as much as 9.37 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding U.S. regulatory probes.
* India's main BSE index falls 0.66 percent and the broader NSE index is down 0.8 percent, heading towards their fourth consecutive session of declines. * Asian stocks slid and the dollar rose to a 4-1/2 year high after Fed Chairman Ben Bernanke's remarks sparked worries of a reduction in U.S. monetary stimulus and after data showed China's factory activity shrank for the first time in seven months in May. * Ranbaxy Laboratories Ltd slumps 6 percent after majority shareholder Daiichi Sankyo
MUMBAI, May 23 - Ranbaxy Laboratories Ltd slumped as much as 6.6 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding U.S. regulatory probes.
MUMBAI - Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy.